Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.34 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411281 | 0.93 | DRD2 (0.42) | DRD2CTSSCTSKCTSB | |
| SCHEMBL6410581 | 0.93 | HDAC11 (0.37) | DRD2CACNA1GKCNH2CTSSCTSK | |
| Hydrochloric Acid SCHEMBL6410577 | 0.92 | HDAC11 (0.36) | DRD2CACNA1GKCNH2CTSSCTSK | |
| SCHEMBL6417456 | 0.91 | CTSS (0.37) | DRD2CTSSCTSKCTSBHDAC1 | |
| SCHEMBL5249697 | 0.90 | DRD2 (0.40) | DRD2CTSSCTSKCTSBDRD3 | |
| SCHEMBL6408368 | 0.90 | CXCR3 (0.36) | HDAC11 | |
| SCHEMBL6411505 | 0.90 | CTSS (0.39) | DRD2CTSSCTSKCTSBHDAC1 | |
| Hydrochloric Acid SCHEMBL6408367 | 0.89 | CXCR3 (0.36) | HDAC11 | |
| SCHEMBL6409182 | 0.88 | HPGD (0.35) | DRD2CACNA1GCTSSCTSK | |
| SCHEMBL6408718 | 0.88 | ROCK2 (0.42) | DRD2CACNA1GDRD4DRD3HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | DRD2 1775/4885CACNA1G 2415/4885KCNH2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.